



HepQuant holding its 2017 Scientific Advisory Board Meeting in Washington D.C. on Saturday, October 21st

DENVER (September 29th, 2017) -- HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced it will be holding its 2017 Scientific Advisory Board Meeting in Washington D.C. on Saturday, October 21st. HepQuant will work with thought leaders in the field of Hepatology to optimize current and future research, development, and commercialization of its technology for measuring global liver function. HepQuant will be hosting this meeting while attending The Liver Meeting[®] 2017, or the 69th AASLD Annual Meeting.

This is not an official function/event of the American Association for the Study of Liver Diseases.

About HepQuant

HepQuant products are investigational combination drug / diagnostic devices and have not yet been evaluated or approved by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process. For additional information, please visit our website at www.hepquant.com.

MEDIA CONTACT

Tom Kennedy, Corporate Communications

Ph: (303) 548-3056 | E: tom.kennedy@hepquant.com